World Health Organization and International League of Associations for Rheumatology Core Endpoints for Symptom Modifying Antirheumatic Drugs in Rheumatoid Arthritis Clinical Trials
作者： D T Felson , P Tugwell , J P Edmonds , J R Kirwan , M Boers
DOI:
关键词:
摘要: The WHO/ILAR core set of endpoints for rheumatoid arthritis clinical trials signifies progress in a continuing worldwide effort. This includes the following measures: pain, patient global assessment, physical disability, swollen joints, tender acute phase reactants, and physician assessment; studies one or more years' duration, radiographs joints should be performed.
参考文章(19)
J F Fries, P W Spitz, D Y Young, The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. The Journal of Rheumatology. ,vol. 9, pp. 789- 793 ,(1982)
Felson Dt, Choosing a core set of disease activity measures for rheumatoid arthritis clinical trials. The Journal of Rheumatology. ,vol. 20, pp. 531- ,(1993)
Kerr L. White, Improved medical care statistics and the health services system. Public Health Reports. ,vol. 82, pp. 847- 854 ,(1967) , 10.2307/4593149
Andre L. Delbecq, Andrew H. Van de Ven, David H. Gustafson, Group Techniques for Program Planning: A Guide to Nominal Group and Delphi Processes ,(1986)
D L Scott, T D Spector, T Pullar, B McConkey, What should we hope to achieve when treating rheumatoid arthritis Annals of the Rheumatic Diseases. ,vol. 48, pp. 256- 261 ,(1989) , 10.1136/ARD.48.3.256
Jennifer J. Anderson, David T. Felson, Robert F. Meenan, H. James Williams, Which traditional measures should be used in rheumatoid arthritis clinical trials Arthritis & Rheumatism. ,vol. 32, pp. 1093- 1099 ,(1989) , 10.1002/ANR.1780320907
David T. Felson, Jennifer J. Anderson, Maarten Boers, Claire Bombardier, Miriam Chernoff, Bruce Fried, Daniel Furst, Charles Goldsmith, Stephanie Kieszak, Robert Lightfoot, Harold Paulus, Peter Tugwell, Michael Weinblatt, Rudolph Widmark, H. James Williams, Frederick Wolfe, The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials Arthritis & Rheumatism. ,vol. 36, pp. 729- 740 ,(1993) , 10.1002/ART.1780360601
Harold E. Paulus, Marlene J. Egger, John R. Ward, H. James Williams, Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo Arthritis & Rheumatism. ,vol. 33, pp. 477- 484 ,(1990) , 10.1002/ART.1780330403
J. T. Scott, Advances in Assessing Rheumatoid Arthritis Annals of the Rheumatic Diseases. ,vol. 43, pp. 7- 7 ,(1984) , 10.1136/ARD.43.1.7
P. L. C. M. VAN RIEL, PROVISIONAL GUIDELINES FOR MEASURING DISEASE ACTIVITY IN CLINICAL TRIALS ON RHEUMATOID ARTHRITIS Rheumatology. ,vol. 31, pp. 793- 794 ,(1992) , 10.1093/RHEUMATOLOGY/31.12.793